SRX Global Inc. — Form 8-K
Filed August 28, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
On August 27, 2026, SRX Global Inc. authorized and issued 4,000 shares of Series C Convertible Preferred Stock (par $0.001, Stated Value $1,000/share). The first closing involved 3,579 Series C shares to a single buyer for $2,862,500 consideration (paid via assignment of $2,812,500 principal + $50,000 accrued interest from CERO Therapeutics convertible notes). Shares convert to common stock at $2.1888 (subject to adjustment), with 15% default dividend rate upon triggering events, 4.99% beneficial ownership cap, and extensive anti-dilution/liquidation preference provisions. Required Reserve: 200% of conversion shares at Alternate Conversion Price. Conversion floor of $2.1888 applies pre-stockholder approval only.
Why this rating
Moderate dilution event: ~$2.86M capital raise is ~31% of company's $9.1M market cap. Series C preferred has strong holder protections (conversion caps, anti-dilution, liquidation preference at 125%) but typical for distressed financing. No immediate revenue or operational impact disclosed; material for small cap but standard preferred issuance mechanics.
See more from August 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.